Research ArticleCancer

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade

See allHide authors and affiliations

Science Translational Medicine  25 Nov 2015:
Vol. 7, Issue 315, pp. 315ra188
DOI: 10.1126/scitranslmed.aac4925

Article Information

vol. 7 no. 315 315ra188

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 14, 2015
  • Accepted for publication October 15, 2015
  • .

Author Information

  1. Philipp Müller1,*,
  2. Matthias Kreuzaler1,
  3. Tarik Khan2,,
  4. Daniela S. Thommen1,3,
  5. Kea Martin1,
  6. Katharina Glatz4,
  7. Spasenija Savic4,
  8. Nadia Harbeck5,6,
  9. Ulrike Nitz6,7,8,
  10. Oleg Gluz6,8,
  11. Michael von Bergwelt-Baildon9,
  12. Hans Kreipe6,10,
  13. Sai Reddy2,
  14. Matthias Christgen6,10 and
  15. Alfred Zippelius1,3,*
  1. 1Department of Biomedicine, University Hospital and University of Basel, CH-4031 Basel, Switzerland.
  2. 2Department of Biosystems Science and Engineering, ETH Zürich, CH-4058 Basel, Switzerland.
  3. 3Department of Medical Oncology, University Hospital Basel, CH-4031 Basel, Switzerland.
  4. 4Institute of Pathology, University Hospital Basel, CH-4031 Basel, Switzerland.
  5. 5Breast Center, Department of Obstetrics and Gynecology, University of Munich, D-81377 Munich, Germany.
  6. 6West German Study Group, D-41061 Mönchengladbach, Germany.
  7. 7Women’s Clinic, Heinrich Heine University Düsseldorf, D-40225 Düsseldorf, Germany.
  8. 8Breast Center Niederrhein, Ev. Bethesda Hospital, D-41061 Mönchengladbach, Germany.
  9. 9First Department of Internal Medicine, University of Cologne, D-50937 Cologne, Germany.
  10. 10Institute of Pathology, Hannover Medical School, D-30625 Hannover, Germany.
  1. *Corresponding author. E-mail: ph.mueller{at}unibas.ch (P.M.); alfred.zippelius{at}usb.ch (A.Z.)
  • Present address: Pharmaceutical Development and Supplies, Pharma Technical Development, F. Hoffmann–La Roche Ltd., 4070 Basel, Switzerland; Center for Cellular Imaging and NanoAnalytics, Biozentrum, University of Basel, 4058 Basel, Switzerland.

Altmetric

Article usage

Article usage: November 2015 to August 2020

AbstractFullPdf
Nov 20151404313935
Dec 20151296385828
Jan 20161106118342
Feb 2016916122265
Mar 201680999278
Apr 201655755161
May 201660761176
Jun 2016133393191
Jul 2016119468163
Aug 201653149107
Sep 201655879130
Oct 201641255118
Nov 201636449118
Dec 20163565277
Jan 201750159132
Feb 20172984767
Mar 20173085190
Apr 20174013974
May 20173584772
Jun 20172764881
Jul 20172323460
Aug 20172733952
Sep 20172663660
Oct 20174204665
Nov 20172773764
Dec 20171962260
Jan 20182143152
Feb 20182143151
Mar 20181634662
Apr 20182182443
May 20181892145
Jun 20181801527
Jul 20181492544
Aug 2018992541
Sep 20181302647
Oct 20181505956
Nov 20181414033
Dec 20181223530
Jan 20191332038
Feb 20191403348
Mar 20191213245
Apr 2019874645
May 20191244339
Jun 20191134758
Jul 20191004235
Aug 2019972329
Sep 2019973824
Oct 2019883753
Nov 2019831421
Dec 20191152326
Jan 2020662216
Feb 2020582521
Mar 2020662129
Apr 2020871526
May 2020732430
Jun 2020852625
Jul 2020372021
Aug 20201102

Stay Connected to Science Translational Medicine